Other atherogenic lipid particles

1 paper1 finding

Interventions

1

Enlicitide

downin humans1

1 study

Enlicitide decreases other atherogenic lipid particles in humans.
“reduced other atherogenic lipid particles at 24 weeks in patients with hypercholesterolemia”
Reviewhypercholesterolemia24 weeks
Enlicitide: The First Oral PCSK9i for Lowering Low-Density Lipoprotein Cholesterol
The Annals of pharmacotherapyOct 14, 2026

More on Enlicitide

Latest

1 in 12 months

The Annals of PharmacotherapyOct 14

Enlicitide: The First Oral PCSK9i for Lowering Low-Density Lipoprotein Cholesterol

Systematic reviewEnlicitide